Regeneron Pharmaceuticals (REGN) Cash from Financing Activities (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Cash from Financing Activities of -$1.2 billion for Q2 2026, down 8.54% year-over-year from -$1.3 billion in Q2 2025, and down 52.66% quarter-over-quarter from -$802.2 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$1.2 billion for Q2 2026.
- In Q2 2026, Cash from Financing Activities fell 8.54% year-over-year to -$1.2 billion; the TTM figure through Jun 2026 stood at -$3.5 billion (up 11.59% YoY), while the FY2025 annual figure was -$3.7 billion, down 68.84% from the prior year.
- Cash from Financing Activities for Q2 2026 stood at -$1.2 billion, down from -$802.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $64.7 million in Q1 2022, with the low at -$1.2 billion in Q2 2026.
- The 5-year median for Cash from Financing Activities is -$624.1 million (2023), against an average of -$596.8 million.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities soared 117.66% in 2022, then plunged 2412.53% in 2025.
- Regeneron Pharmaceuticals' Cash from Financing Activities stood at -$247.6 million in 2022, then plunged by 80.17% to -$446.1 million in 2023, then plunged by 154.54% to -$1.1 billion in 2024, then surged by 31.3% to -$780.1 million in 2025, then sank by 56.98% to -$1.2 billion in 2026.
- Business Quant data shows REGN's Cash from Financing Activities at -$1.2 billion in Q2 2026, -$802.2 million in Q1 2026, and -$780.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -181.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.22 Bn |
| Jun 30, 2026 | -1.22 Bn |
| Mar 31, 2026 | -802.20 Mn |
| Mar 31, 2026 | -802.20 Mn |
| Dec 31, 2025 | -780.10 Mn |
| Dec 31, 2025 | -780.10 Mn |
| Sep 30, 2025 | -717.90 Mn |
| Sep 30, 2025 | -717.90 Mn |
| Jun 30, 2025 | -1.13 Bn |
| Jun 30, 2025 | -1.13 Bn |
| Mar 31, 2025 | -1.09 Bn |
| Mar 31, 2025 | -1.09 Bn |
| Dec 31, 2024 | -1.14 Bn |
| Dec 31, 2024 | -1.14 Bn |
| Sep 30, 2024 | -634.00 Mn |
| Sep 30, 2024 | -634.00 Mn |
| Jun 30, 2024 | -478.10 Mn |
| Jun 30, 2024 | -478.10 Mn |
| Mar 31, 2024 | 47.10 Mn |
| Mar 31, 2024 | 47.10 Mn |